A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.
Checked against the public recordLast updated Jul 1, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Synta Pharmaceuticals Corp.
- Interventions being studied
- Drug: Docetaxel; Drug: Ganetespib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC) * Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1 * Prior therapy defined as 1 prior systemic therapy for advanced disease * Documented disease progression during or following most first line therapy for advanced disease * Adequate hematologic, hepatic, renal function Exclusion Criteria: * Epidermal growth factor receptor (EGFR) mutations * Anaplastic lymphoma kinase (ALK) translocations * Predominantly squamous, adenosquamous or unclear histologic type * Active or untreated central nervous system (CNS) metastases * Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin * Serious cardiac illness or medical conditions * Pregnant or lactating women * Uncontrolled intercurrent illness
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Arizona Oncology Associates PC- NAHOAFlagstaff, Arizona
- Arizona Oncology Associates, PC- NAHOAPrescott Valley, Arizona
- Northern Arizona Hematology & Oncology AssociatesSedona, Arizona
- Arizona Clinical Research Center, Inc.Tucson, Arizona
- Pacific Cancer Medical Center, IncAnaheim, California
- Comprehensive Blood & Cancer CenterBakersfield, California
- City of Hope Comprehensive Breast Cancer CenterDuarte, California
- UC San Diego Moores Cancer CenterLa Jolla, California
- Loma Linda University Cancer CenterLoma Linda, California
- VA Greater Los Angeles Healthcare SystemLos Angeles, California
- Ronald Reagan UCLA Medical CenterLos Angeles, California
- St. Joseph Hospital, Center for Cancer Prevention and TreatmentOrange, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 1, 2016. Always confirm current availability with the study team.